Schriftgut
Lanvis/Thioguanin-Tabletten 40 mg (The Wellcome Foundation Limited): Bd. 3
- Reference number
-
Bundesarchiv, BArch DQ 116/4317
- Language of the material
-
deutsch
- Context
-
Institut für Arzneimittelwesen (IFAR) der DDR >> DQ 116 Institut für Arzneimittelwesen (IFAR) der DDR >> Zulassung von im Ausland hergestellten Arzneimitteln in der DDR (Importe) >> Großbritannien (00/09) >> Lanvis/Thioguanin-Tabletten 40 mg (The Wellcome Foundation Limited)
- Holding
-
BArch DQ 116 Institut für Arzneimittelwesen (IFAR) der DDR
- Provenance
-
Institut für Arzneimittelwesen der DDR (IFAR), 1974-1990
- Date of creation
-
1971
- Other object pages
- Last update
-
30.01.2024, 2:26 PM CET
Data provider
This object is provided by:
Bundesarchiv. If you have any questions about the object, please contact the data provider.
Bundesarchiv. If you have any questions about the object, please contact the data provider.
Object type
- Schriftgut
Associated
- Institut für Arzneimittelwesen der DDR (IFAR), 1974-1990
Time of origin
- 1971
Other Objects (12)
Lanvis/Thioguanin-Tabletten 40 mg (The Wellcome Foundation Limited): Bd. 2
Lanvis/Thioguanin-Tabletten 40 mg (The Wellcome Foundation Limited): Bd. 4
Lanvis/Thioguanin-Tabletten 40 mg (The Wellcome Foundation Limited): Bd. 1
Myleran/Busulfan-Tabletten 2 mg (The Wellcome Foundation Limited): Bd. 2
Myleran/Busulfan-Tabletten 2 mg (The Wellcome Foundation Limited): Bd. 1
Busulfan Tabletten 2 mg (Farmos Group Limited)
Tioridil-Tabletten 100 mg (Farmos Group Limited)
Furesis-Tabletten und Furesis-special-Tabletten 500 mg (Farmos Group Limited)
Kenacort-Tabletten 4 mg (E.R. Squibb & Sons Limited)
Metypred (Orion Corporation Limited/Orion Pharmaceutica): 4 mg Tabletten
Metypred (Orion Corporation Limited/Orion Pharmaceutica): Tabletten 16 mg
Metypred (Orion Corporation Limited/Orion Pharmaceutica): 4 mg Tabletten, 40 mg/ml Depotinjektion-Ampullen und 125 mg Ampullen
Lanvis/Thioguanin-Tabletten 40 mg (The Wellcome Foundation Limited): Bd. 2
Lanvis/Thioguanin-Tabletten 40 mg (The Wellcome Foundation Limited): Bd. 4
Lanvis/Thioguanin-Tabletten 40 mg (The Wellcome Foundation Limited): Bd. 1
Myleran/Busulfan-Tabletten 2 mg (The Wellcome Foundation Limited): Bd. 2
Myleran/Busulfan-Tabletten 2 mg (The Wellcome Foundation Limited): Bd. 1
Busulfan Tabletten 2 mg (Farmos Group Limited)
Tioridil-Tabletten 100 mg (Farmos Group Limited)
Furesis-Tabletten und Furesis-special-Tabletten 500 mg (Farmos Group Limited)
Kenacort-Tabletten 4 mg (E.R. Squibb & Sons Limited)
Metypred (Orion Corporation Limited/Orion Pharmaceutica): 4 mg Tabletten
Metypred (Orion Corporation Limited/Orion Pharmaceutica): Tabletten 16 mg
Metypred (Orion Corporation Limited/Orion Pharmaceutica): 4 mg Tabletten, 40 mg/ml Depotinjektion-Ampullen und 125 mg Ampullen
Lanvis/Thioguanin-Tabletten 40 mg (The Wellcome Foundation Limited): Bd. 2
Lanvis/Thioguanin-Tabletten 40 mg (The Wellcome Foundation Limited): Bd. 4
Lanvis/Thioguanin-Tabletten 40 mg (The Wellcome Foundation Limited): Bd. 1
Myleran/Busulfan-Tabletten 2 mg (The Wellcome Foundation Limited): Bd. 2
Myleran/Busulfan-Tabletten 2 mg (The Wellcome Foundation Limited): Bd. 1
Busulfan Tabletten 2 mg (Farmos Group Limited)
Tioridil-Tabletten 100 mg (Farmos Group Limited)
Furesis-Tabletten und Furesis-special-Tabletten 500 mg (Farmos Group Limited)
Kenacort-Tabletten 4 mg (E.R. Squibb & Sons Limited)
Metypred (Orion Corporation Limited/Orion Pharmaceutica): 4 mg Tabletten
Metypred (Orion Corporation Limited/Orion Pharmaceutica): Tabletten 16 mg